Gene Finding Lends Clues to Blood Pressure
Problems
A new genetic discovery may help explain
why some people develop high blood pressure
and others do not, and why some people's
blood pressure increases as they age,
according to a report in the American
Journal of Hypertension .
The
findings also give new insight into
how the kidneys govern the balance of
salt in the body, a crucial task for regulating
blood pressure.
And,
it reveals how a gene already linked to
behavior and mental health can play a
role in the body, as well as the brain.
The
researchers say that one in four adults
in the US has high blood pressure, also
called hypertension - and many do not
know it.
If
high blood pressure is not lowered with
the help of diet, exercise, and medication,
it can dramatically raise the risk of
heart attack, stroke, or kidney problems.
Blood
pressure, measured with a blood pressure
cuff and stethoscope by a nurse or other
healthcare provider, is the force of the
blood pushing against the artery walls.
Each time the heart beats, it pumps blood
into the arteries, resulting in the highest
blood pressure as the heart contracts.
Two
numbers are recorded when measuring blood
pressure. The higher number, or systolic
pressure, refers to the pressure inside
the artery when the heart contracts and
pumps blood through the body.
The
lower number, or diastolic pressure, refers
to the pressure inside the artery when
the heart is at rest and is filling with
blood.
Both
the systolic and diastolic pressures are
recorded as "mm Hg" (millimeters of mercury).
This recording represents how high the
mercury column is raised by the pressure
of the blood.
Individuals
are considered to have high blood pressure
if their blood pressure is greater than
140 mm Hg systolic, or 90 mm Hg diastolic.
The
researchers report that in the study,
blood pressure was higher and more likely
to rise with age among persons who had
an extra-long form of a gene called DRD4.
They
made the discovery by studying the genes
of 864 people from 286 families taking
part in a long-term blood pressure genetics
study called GenNet.
The
families all live in or near the town
of Tecumseh, Mich., which since 1958 has
been home to a U-M clinical research initiative
called the Tecumseh Community Health Study.
The
finding of a link between DRD4 and blood
pressure came as a surprise to researchers
who tested this gene initially to look
at genetics and behavior.
Cells
use the DRD4 gene to make a receptor for
a chemical called dopamine, which transmits
messages between cells.
Dopamine
is best known for its role in the brain,
where it is involved in feelings of pleasure,
and in governing movement.
Some
studies have suggested that variations
in genes for dopamine receptors are linked
to certain behavioral traits or personality
types.
But
in recent years dopamine has also been
found to play a role in regulating the
release of salt by the kidneys. The new
finding adds more evidence for that role.
"While
many genes are involved in blood pressure
and the inherited risk of developing hypertension,
we're learning that variations in genes
for dopamine receptors play a significant
role," says senior author Dr. Alan Weder,
professor of internal medicine at the
University of Michigan Medical School.
"As
we learn more, we may be able to determine
which patients need the most aggressive
blood pressure treatment, and to develop
drugs that can lower blood pressure by
intervening directly in the proximal tubules
of the kidneys, where dopamine acts -
something today's drugs don't do," Dr.
Weder explains.
The
new study is the first to show that the
DRD4 receptor plays a role in the regulation
of blood pressure by the kidneys, and
to show that a common variation in the
gene is associated with higher blood pressure.
Two
other dopamine receptors have previously
been shown to be linked to blood pressure
regulation.
Blood
pressure, especially the systolic pressure,
tends to rise as a person gets older.
And in older people, high systolic pressure
is considered the greatest risk factor
for cardiovascular disease.
That
is one reason the new finding is especially
significant, says Dr. Weder.
"This
gene variation may be useful in developing
a predictor of which patients are likely
to have a rapid rise in blood pressure
as they age, and may need more aggressive
monitoring and treatment," he says.
However,
he and his co-authors say, no one gene
variation is enough to predict an individual
person's blood pressure tendencies, and
further research on the genes involved
in hypertension will be needed.
The
other important implication of the finding
is to create a fuller understanding of
dopamine's action in the kidneys, and
changes in that action brought about by
variations in the receptor gene.
Dopamine
in the kidney helps the body respond to
large loads of sodium, or salt, coming
into the body.
After
a salty meal, for example, higher levels
of dopamine can be detected in the urine
after being produced and used by the kidneys
to regulate the removal of salt from the
body.
Always
consult your physician for more information. |
The use of medicated stents markedly improves
the clinical outcomes of patients who
develop blockages in aging veins surgically
grafted onto the heart, according to a
report in Catheterization and Cardiovascular
Interventions .
The Society for Cardiovascular Angiography
and Intervention 's journal reports that
compared to conventional bare metal stents,
drug-eluting stents significantly cut
the rates of heart attack and repeat procedures,
both of which are indicators of renarrowing
- or restenosis - within the stent.
Maintaining
blood flow to the heart through aging
vein grafts clogged with cholesterol plaque,
blood clots, and other debris is especially
challenging, the researchers say.
"There
was a fourfold reduction in the incidence
of restenosis with the medicated stents,"
says Dr. Raj Makkar, co-director of the
Cardiovascular Intervention Center at
Cedars Sinai Medical Center in Los Angeles.
"At least over the short term, that's
very encouraging."
Drug-eluting
stents slowly release medication that
prevents the overgrowth of scar tissue
inside the stent, and have been shown
to significantly reduce the risk of restenosis
in the natural arteries of the heart.
Treating
worn and diseased vein grafts is more
challenging, however. In fact, within
five to 10 years, half of all vein grafts
become diseased, necessitating either
stenting or repeat bypass surgery in some
cases.
The
study analyzed data from 223 consecutive
patients who had a stenting procedure
to restore blood flow through clogged
vein grafts, 139 of whom were treated
with a drug-eluting stent and 84 of whom
were treated with a bare metal stent.
Patients
had undergone the original bypass surgery
an average of nearly 8 years earlier.
During
nine months of follow-up, 4 percent of
patients treated with a drug-eluting stent
experienced a heart attack, as compared
to 20 percent of patients treated with
a bare metal stent.
Similarly,
10 percent of patients treated with a
drug-eluting stent needed a repeat procedure
to reopen the vein graft, as compared
to 37 percent of patients treated with
bare metal stents.
The
combined rates of heart attack, repeat
procedure, and death were 10 percent and
37 percent, respectively.
The
Cedars Sinai researchers are continuing
to follow-up patients to determine whether
drug-eluting stents offer a similar advantage
over the long run.
Since
plaque tends to build up throughout vein
grafts, patients may develop new blockages
that require additional stenting procedures.
"We
can't expect drug-eluting stents to eliminate
all problems with bypass grafts, but this
study suggests it is reasonable to use
medicated stents to treat these patients,"
Dr. Makkar says.
Always
consult your physician for a diagnosis.
(Our
Organization is not responsible for the
content of Internet sites.)
American
College of Cardiology
American
Heart Association
American
Journal of Hypertension
Centers
for Disease Control and Prevention (CDC)
Go
Red for Women Campaign, AHA
National
Heart, Lung, and Blood Institute (NHLBI)
National
Institutes of Health (NIH)
National
Library of Medicine
National
Women's Health Information Center
Society
for Cardiovascular Angiography and Intervention
US
Health and Human Services
|